French Medical Robotics Manufacturers (2026)

French medical robotics manufacturers are a small, technically dense group of companies building image-guided systems for cancer ablation, interventional cardiology, orthopaedic surgery, and laparoscopy. Quantum Surgical in Montpellier, Robocath in Rouen, eCential Robotics (formerly Surgivisio) in Grenoble, and Endocontrol in Grenoble anchor the cluster. This guide covers who they are, what is happening in 2025-2026, and how to reach hospital buyers.

The French Medical Robotics Cluster

There is no single industrial park. French medical robotics is spread across four cities, each tied to a university hospital and an engineering school. Montpellier hosts Quantum Surgical. Rouen hosts Robocath. Grenoble holds the densest sub-cluster, with eCential Robotics, Endocontrol, and a steady stream of spin-outs from the TIMC research lab and the Universite Grenoble Alpes. Strasbourg sits alongside the cluster through the IHU Strasbourg institute for image-guided surgery, which incubates and partners with industrial firms across the country.

These companies sit inside a larger medical device sector. According to the US International Trade Administration country commercial guide on France medical devices, the French medtech industry runs roughly EUR 37.4 billion in turnover, employs around 95,000 people, and exports EUR 9.5 billion per year, with 92% of firms classified as SMEs. France is the second-largest medtech market in Western Europe, behind Germany. The industry’s trade association, SNITEM, represents most of these firms.

The wider opportunity is much bigger than France. According to Towards Healthcare market sizing for surgical robotics, the global robotic surgery market was around USD 13.79 billion in 2025 and is projected to compound at roughly 16% per year through the mid-2030s. North America still captures the largest share at around 38%, but European hospitals are catching up on capital plans, and French firms are positioned to compete in segments where US incumbents like Intuitive Surgical do not have a finished product yet.

The Companies Worth Knowing

Quantum Surgical (Montpellier)

Quantum Surgical builds Epione, an image-guided robotic platform for percutaneous tumour ablation. The robot plans needle trajectories on CT or MRI, places needles inside the patient, and supports physicians during the ablation. According to Quantum Surgical’s FDA clearance announcement, Epione received FDA 510(k) clearance for all abdominal cancers in May 2023, covering liver, kidney, adrenal, and pancreatic tumour indications. The robot is installed in around 15 hospitals across Europe and the US, with over 1,400 patients treated. President and Co-founder Bertin Nahum said the abdominal clearance lets “physicians treat all abdominal tumours at an early stage” and accelerates US deployment.

In September 2025, Epione received CE-mark approval for bone tumours and metastases, extending the system beyond soft tissue. A multi-centre clinical study, EPIOS, began enrolling for US approval extension, with the first patient treated in April 2026.

Robocath (Rouen)

Robocath builds R-One+, a robotic platform for percutaneous coronary intervention (PCI). The cardiologist sits at a shielded workstation and manipulates guidewires, balloons, and stents remotely while the robot handles the catheter movement inside the patient. According to MedTech Dive’s coverage of the Stereotaxis acquisition, R-One+ is the only commercially available robotic solution for percutaneous coronary interventions in Europe, with 15 commercial units installed globally as of April 2026.

In April 2026, Stereotaxis (NYSE: STXS) announced a definitive agreement to acquire Robocath for up to USD 45 million: USD 20 million upfront and up to USD 25 million in contingent payments tied to regulatory and commercial milestones, including FDA clearance of Robocath’s next-generation system. The transaction is expected to close in mid-2026. Until closing, Robocath continues to operate independently and remains the only French interventional cardiology robot on the market. After closing, the company will sit inside a US-listed parent with a broader endovascular platform across electrophysiology, cardiology, and neurointerventions.

eCential Robotics (Grenoble, formerly Surgivisio)

eCential Robotics builds an integrated 2D/3D imaging, navigation, and robotic platform used in spine, orthopaedic, and trauma surgery. The company was founded in 2009 by Stephane Lavallee as Surgivisio, rebranded to eCential Robotics, and according to Investing in Grenoble Alpes secured roughly EUR 100 million in financing, the largest medtech funding round in Grenoble history. The company designs and manufactures all of its products in the Grenoble Alpes Metropole region with close to 100 employees. In June 2025, US-based ChoiceSpine launched a navigation-integrated app for use on the eCential Op.n platform, extending the company’s footprint with US spine OEMs.

Endocontrol (Grenoble)

Endocontrol builds compact robotic devices for laparoscopic surgery, helping surgeons control instruments and laparoscopes with fewer hands at the table. It is smaller than the other three but sits inside the same Grenoble cluster, selling into European hospitals running general, urological, and gynaecological laparoscopy.

Eos Imaging and a note on ownership

Eos Imaging was founded in France in 2001 and pioneered low-dose 2D/3D imaging for orthopaedics. It is now an Alphatec subsidiary after the US group acquired it in 2023. It still operates from Paris with French manufacturing, but it is no longer French-owned. The pattern repeats in medical robotics: French firms get built to clinical maturity, and US acquirers buy them on the way to scale.

France 2030: Why Robotics Sits Inside a EUR 7.5B Health Plan

The Macron government’s France 2030 plan committed EUR 7.5 billion to a Health Innovation Plan, with EUR 400 million inside that pot tagged for medical devices. According to French Healthcare’s overview of the plan, the medical device allocation funds surgical robots, smarter implants and prostheses, and digital solutions for mental health, with the goal of returning France to the top of European health innovation.

For a French robotics SME, the practical effect is real. Public co-funding through Bpifrance, EIC Accelerator grants, and partnerships with INRIA and the IHU institutes lowers the cost of building a first commercial system. The hard part is what comes after: selling it.

The 2025-2026 Trade Environment

Three dynamics are shaping commercial conditions for French robotics manufacturers in 2026.

First, hospital capital budgets are tight in Europe. Public hospitals across France, Germany, Italy, and Spain are running multi-year deficits, and robotic capital purchases (typically EUR 1M to EUR 3M per system, plus consumables) are landing inside extended evaluation cycles. Buyers want longer pilots, more clinical data, and clear ROI models tied to throughput and complications.

Second, US tariff conditions and reimbursement signals are noisy. The CMS reimbursement environment for robotic procedures is favourable on the whole, but French firms exporting to the US still need 510(k) or PMA pathways, GPO contracts, and IDN-level adoption to scale. Each of those steps takes time, and US competitors have home-market advantages on installed-base and reference accounts.

Third, M&A is accelerating. The Robocath sale to Stereotaxis is one example. Eos Imaging to Alphatec was another. US incumbents are buying French clinical-stage robotics rather than building. For founders, that is an exit path. For commercial teams, it means the addressable buyer set inside France is shifting toward US-headquartered parent companies with their own procurement preferences.

Conventional Sales Channels Under Pressure

The classic French playbook for selling a surgical or interventional robot has not collapsed. Every component of it is getting more expensive and harder to scale.

Trade fairs: still mandatory, less differentiating

MEDICA in Dusseldorf, RSNA in Chicago for image-guided systems, HIMSS for digital health, the Cardiovascular Innovations conference, and the European Society of Radiology annual congress are the major events. Booth, freight, demo cadavers, and staffing for a robotics company typically runs EUR 80,000 to EUR 200,000 per fair. Cost per qualified lead lands in the USD 300 to USD 900+ range. Smaller specialised events (BSIR, EuroPCR) generate sharper conversations but reach smaller audiences.

Field reps with surgical training certifications: rare and expensive

A medical robotics rep needs working knowledge of clinical workflows, imaging modalities, sterility, and the regulatory framework of each target market. Most also need clearance to scrub into cases for training and case support. That talent pool is small. Fully-loaded cost per rep with European multi-country coverage runs EUR 180,000 to EUR 280,000 per year, and cost per qualified lead from field reps typically lands in the USD 500 to USD 1,200+ range.

Hospital purchasing groups and consolidated buyers

Inside France, capital equipment purchases are co-ordinated through Groupements Hospitaliers de Territoire (GHT), with UniHA running national public procurement. In the US, robotic capital sits under GPO contracts and IDN-level capital committees. In Germany, university hospitals run their own tenders inside multi-vendor framework agreements. Reaching these buyers cold is hard. Doing it in their native language is harder.

Equipment leasing dealers and pay-per-procedure models

To soften the EUR 1M+ price tag, robotics firms work with equipment leasing dealers or offer pay-per-procedure contracts. That smooths cash flow for the hospital but locks the manufacturer into long-tail support obligations that slow geographic expansion.

Cold calling: still effective when done properly

Cold outreach into hospital procurement, interventional cardiology chiefs, oncology committee chairs, and orthopaedic department heads still works, especially in the buyer’s native language. The problem is scale. Building an in-house team that can run sharp cold conversations in French, English, German, Italian, Spanish, Arabic, Portuguese, and Japanese is prohibitively expensive for a 30 to 150-person SME.

How AI-Powered Outbound Fits French Robotics Manufacturers

A scalable AI outbound engine is not a replacement for the surgeon site visits, the cadaver labs, or the EuroPCR live cases. It is a way of running the cold and warm top-of-funnel work at a scale and price point that a 50 to 150-person French firm cannot match by hiring.

Targeted hospital outreach by clinical specialty. The engine identifies named buyers: interventional cardiology chiefs for Robocath-style platforms, interventional radiology and oncology chairs for Epione-style ablation, spine and orthopaedic chiefs for eCential-style navigation. Outreach references the prospect’s procedure volume, hospital reputation, and clinical interests.

Signal-aware targeting. Capital budget cycles, new hybrid OR construction, radiology suite buildouts, hospital expansion announcements, GHT tender windows, and surgeon mobility between hospitals are all signals the engine watches. Most field reps cannot do this at scale across 12 countries.

Compliance-aware personalisation. Each message references the right framework per market: MDR for the EU, FDA 510(k) or PMA for the US, PMDA for Japan, ANVISA for Brazil, SFDA for Saudi Arabia, NMPA for China. Your regulatory team configures inputs once, and the engine applies them per geography.

Native-language reach. French, English, German, Italian, Spanish, Arabic, Portuguese, and Japanese run concurrently. Your clinical specialists only enter the conversation once a prospect is genuinely qualified.

Multi-market diversification at speed. When a distributor underperforms or a US tariff event shifts the cost equation, the engine can re-target the Gulf, Southeast Asia, Latin America, or adjacent EU geographies within days.

Cost per qualified lead lands in the USD 150 to USD 300 range depending on geography and clinical category, and the marginal cost trends down as the engine learns. Trade fairs scale linearly. Field reps scale worse than linearly. AI outbound compounds.

For broader French context, the French pharma and biotech exporters guide and the French surgical instrument manufacturers guide sit alongside this post. To see what an engine setup looks like end to end, the how it works page walks through the configuration for regulated B2B manufacturers.

What the First 90 Days Look Like

Days 1-30. Define the buyer profile. Interventional cardiology, interventional radiology, oncology, spine, orthopaedics, or laparoscopy departments? Which geographies match your CE-mark and 510(k) coverage today, and which need extra registration first? Build messaging that leads with clinical evidence, regulatory status, installed base, and the French engineering heritage that still carries weight in regulated markets.

Days 31-60. Run outreach into two or three priority markets. Watch reply rates per clinical specialty and refine. First positive replies from clinical chiefs and procurement officers typically arrive here.

Days 61-90. Expand into additional markets and buyer segments. Layer in fresh signals: new hybrid OR construction, GHT renewal cycles, new department launches, surgeon mobility. By this point you should have multiple active conversations and early qualified opportunities.

Frequently Asked Questions

Who are the leading French medical robotics manufacturers?

Quantum Surgical in Montpellier (Epione, percutaneous tumour ablation), Robocath in Rouen (R-One+, percutaneous coronary intervention, being acquired by Stereotaxis with closing in mid-2026), eCential Robotics in Grenoble (spine and orthopaedic navigation, formerly Surgivisio), and Endocontrol in Grenoble (laparoscopic surgery devices). Eos Imaging was founded in France but is now an Alphatec subsidiary headquartered out of the US.

Where is French medical robotics concentrated geographically?

Grenoble holds the densest cluster, with eCential Robotics, Endocontrol, the TIMC research lab, and Universite Grenoble Alpes spin-outs. Montpellier hosts Quantum Surgical. Rouen hosts Robocath. Strasbourg sits alongside the cluster via the IHU Strasbourg institute for image-guided surgery. Paris and Ile-de-France house corporate offices and some imaging firms.

What is France 2030’s role in medical robotics?

France 2030 committed EUR 7.5 billion to the Health Innovation Plan, with EUR 400 million inside that pot tagged for medical devices, including surgical robots. The funding is channelled through Bpifrance, EIC Accelerator grants, IHU partnerships, and research collaborations with INRIA. The goal is to return France to the top of European health innovation by 2030.

How does the Stereotaxis acquisition affect Robocath’s customers?

The transaction was announced in April 2026 and is expected to close in mid-2026. Until closing, Robocath operates independently, and its 15 installed R-One+ systems continue to be supported by the existing team. Post-close, the company sits inside Stereotaxis’s broader endovascular platform, which spans electrophysiology, interventional cardiology, and neurointerventions. FDA clearance of Robocath’s next-generation system is one of the contingent milestones inside the deal.

Can AI outbound handle the regulatory complexity of medical robotics sales?

Yes. The engine is configured around your specific certifications and clinical evidence. Outreach references the relevant framework per market: MDR for the EU, FDA 510(k) or PMA for the US, SFDA for Saudi Arabia, PMDA for Japan, ANVISA for Brazil, NMPA for China. Your regulatory and clinical affairs team provides the inputs during setup, and the system applies them inside personalised messaging per geography and per buyer.

Does this replace attending MEDICA, RSNA, or EuroPCR?

No. The major clinical and trade events still matter for live demonstrations, surgeon feedback, regulatory conversations, and KOL relationships. AI outbound complements them by identifying and warming target buyers before the event and following up systematically afterward, so the booth investment generates returns 12 months a year instead of four days in November.

The Bottom Line

French medical robotics is a small, technically dense industry sitting inside a EUR 37.4 billion medtech economy with public backing through France 2030. Quantum Surgical, Robocath, eCential Robotics, and Endocontrol are clinically credible and commercially under-resourced relative to their US peers. The pressure points are real: tight European hospital capital budgets, noisy US conditions, accelerating M&A, and rising costs across every conventional channel.

The French firms that build direct outbound pipelines into hospital procurement teams, clinical chiefs, and capital committees will compound their position through the cycle. The ones still waiting for the next MEDICA will keep competing with 5,000 other exhibitors for the same procurement officers.

If you build medical robotics or image-guided systems in France and want to see what a scalable outbound engine looks like in your specific clinical category, start a conversation with us.